Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CETN1
REST API REST API
Homo sapiens
CETN1 is differentially expressed in 128 experiments: 71 organism parts: testis, testis - interstitial, ... (69 more);, 92 disease states: normal, healthy, ... (90 more);, 30 cell types 75 cell lines 16 compound treatments and 50 other conditions.
Synonyms CEN1, CETN
Orthologs ENSGALG00000007510 (Gallus gallus)   Cetn1 (Mus musculus)   CDC31 (Saccharomyces cerevisiae)   CETN1_BOVIN (Bos taurus)   Cetn1 (Rattus norvegicus)   cetn1 (Xenopus laevis)   (Compare orthologs)
InterPro Term EF-hand, EF_HAND_2, EF_hand_Ca-bd
Gene Ontology Term spindle pole, cell division, cytoskeleton, cytoplasm, ATP-dependent helicase activity, nucleic acid binding, centriole, ATP binding, cell cycle, centrosome, mitosis, cellular response to heat, calcium ion binding, photoreceptor connecting cilium, G-protein beta/gamma-subunit complex binding
UniProt Accession Q12798
Search EB-eye ENSG00000177143
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-2450, E-GEOD-19480, E-MTAB-62, E-MTAB-37, E-GEOD-19466, ... (13 experiments)

Factor Value U/D Experiments
MKN1
1
E-GEOD-15460
NCIH2030
1
E-MTAB-37
MCF7
1
E-MTAB-37
CCFSTTG1
1
E-MTAB-37
SKMES1
1
E-MTAB-37
MCF-7
1
E-GEOD-20081
69 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-MTAB-25, E-GEOD-3920, E-TABM-130, ... (16 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
2
E-TABM-130, E-TABM-145
immortalised T lymphocytes
1
E-GEOD-13909
naive B cell
1
E-TABM-702
leydig cell
1
E-MTAB-25
native fetal RPE
1
E-GEOD-18811
24 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-2466, E-TABM-15, ... (29 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
melanoma
1
E-MTAB-62
FAB: M2 acute myeloid leukemia
1
E-GEOD-12662
prostate cancer
1
E-GEOD-6919
large cell-undifferentiated
1
E-MTAB-62
cancerous
1
E-TABM-15
86 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-412, E-GEOD-3720, ... (9 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
E-GEOD-3720
vanadium pentoxide
1
E-GEOD-5339
Cxcl12
1
E-GEOD-7307
unknown
1
E-GEOD-7307
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
control
31
1
E-GEOD-3284
10 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-21138

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-MEXP-1403

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-GEOD-1926, E-TABM-666, E-GEOD-19519, E-GEOD-6919, ... (19 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-16837, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.52 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM